IGF2 and Hypoglycemia: The hypoglycemia risk of intranasally administered IGF2 is likely to be even lower, since a negligible amount of the intranasally administered compound enters general circulation: whereas 40 I.U. subcutaneous insulin would provoke hypoglycemia in humans, this same dose of intranasal insulin was not associated with acute or chronic hypoglycemia.183